[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fOn_druY3dupnORdiWbxyNHl9_rOBv1ngC4p_iJrHvTU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":49,"rows":56},"University of Aberdeen",[4],172,false,30,2,86185,4,155,[14,17,19,22,24,27,29,31],{"name":15,"count":16},"Healthy",7,{"name":18,"count":16},"Asthma",{"name":20,"count":21},"Obesity",6,{"name":23,"count":21},"Breast Cancer",{"name":25,"count":26},"Cardiovascular Disease",5,{"name":28,"count":11},"Chronic Pain",{"name":30,"count":11},"Type 2 Diabetes",{"name":32,"count":11},"Takotsubo Cardiomyopathy",[34,39,44],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07065383","Rebalancing the Fat Content of the Heart and Muscles","2028-07-31","Semaglutide administration plus dietary counselling and physical activity encouragement",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07070765","Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity","2028-10-31","Sodium-glucose transport-2 (SGLT-2) inhibitors",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04513054","Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy","2028-12-31","Blood collection for genetic analysis",[50,51,52,53,54,55],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[57,80,102,120,140,166,192,210,235,270,294,317,343,366,388,414,439,464],{"intervention":48,"totalTrials":58,"cells":59},1,{"EARLY_PHASE1":60,"PHASE1":63,"PHASE2":65,"PHASE3":67,"PHASE4":69,"NA":71},{"trials":61,"activeCount":62},[],0,{"trials":64,"activeCount":62},[],{"trials":66,"activeCount":62},[],{"trials":68,"activeCount":62},[],{"trials":70,"activeCount":62},[],{"trials":72,"activeCount":58,"soonestReadout":47},[73],{"nctId":45,"briefTitle":46,"status":74,"phases":75,"primaryCompletion":47,"completion":47,"start":76,"enrollment":77,"conditions":78,"interventions":79},"RECRUITING",[55],"2019-03-12",700,[32],[48],{"intervention":38,"totalTrials":58,"cells":81},{"EARLY_PHASE1":82,"PHASE1":84,"PHASE2":86,"PHASE3":88,"PHASE4":90,"NA":92},{"trials":83,"activeCount":62},[],{"trials":85,"activeCount":62},[],{"trials":87,"activeCount":62},[],{"trials":89,"activeCount":62},[],{"trials":91,"activeCount":62},[],{"trials":93,"activeCount":58,"soonestReadout":37},[94],{"nctId":35,"briefTitle":36,"status":74,"phases":95,"primaryCompletion":37,"completion":37,"start":96,"enrollment":97,"conditions":98,"interventions":100},[55],"2025-08-01",60,[99],"Diabetes Mellitus Type 2",[38,101],"Semaglutide plus a personalised and supervised program of resistance and endurance training",{"intervention":101,"totalTrials":58,"cells":103},{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":114},{"trials":105,"activeCount":62},[],{"trials":107,"activeCount":62},[],{"trials":109,"activeCount":62},[],{"trials":111,"activeCount":62},[],{"trials":113,"activeCount":62},[],{"trials":115,"activeCount":58,"soonestReadout":37},[116],{"nctId":35,"briefTitle":36,"status":74,"phases":117,"primaryCompletion":37,"completion":37,"start":96,"enrollment":97,"conditions":118,"interventions":119},[55],[99],[38,101],{"intervention":43,"totalTrials":58,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":132},{"trials":123,"activeCount":62},[],{"trials":125,"activeCount":62},[],{"trials":127,"activeCount":62},[],{"trials":129,"activeCount":62},[],{"trials":131,"activeCount":62},[],{"trials":133,"activeCount":58,"soonestReadout":42},[134],{"nctId":40,"briefTitle":41,"status":74,"phases":135,"primaryCompletion":42,"completion":42,"start":136,"enrollment":137,"conditions":138,"interventions":139},[55],"2025-12-12",70,[23],[43],{"intervention":141,"totalTrials":58,"cells":142},"Isotretinoin",{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":164},{"trials":144,"activeCount":62},[],{"trials":146,"activeCount":62},[],{"trials":148,"activeCount":62},[],{"trials":150,"activeCount":62},[],{"trials":152,"activeCount":62},[153],{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":163},"NCT01404130","A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory","COMPLETED",[54],"2010-11","2008-09",18,[162],"Acne Vulgaris",[141],{"trials":165,"activeCount":62},[],{"intervention":167,"totalTrials":58,"cells":168},"Ketamine",{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":190},{"trials":170,"activeCount":62},[],{"trials":172,"activeCount":62},[],{"trials":174,"activeCount":62},[],{"trials":176,"activeCount":62},[],{"trials":178,"activeCount":62},[179],{"nctId":180,"briefTitle":181,"status":156,"phases":182,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":188},"NCT01306760","The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy",[54],"2014-02","2011-03",40,[187],"Depression",[167,189],"Propofol",{"trials":191,"activeCount":62},[],{"intervention":189,"totalTrials":58,"cells":193},{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":202,"NA":208},{"trials":195,"activeCount":62},[],{"trials":197,"activeCount":62},[],{"trials":199,"activeCount":62},[],{"trials":201,"activeCount":62},[],{"trials":203,"activeCount":62},[204],{"nctId":180,"briefTitle":181,"status":156,"phases":205,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":206,"interventions":207},[54],[187],[167,189],{"trials":209,"activeCount":62},[],{"intervention":211,"totalTrials":58,"cells":212},"sodium nitrite",{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":231,"NA":233},{"trials":214,"activeCount":62},[],{"trials":216,"activeCount":62},[],{"trials":218,"activeCount":62},[],{"trials":220,"activeCount":62},[221],{"nctId":222,"briefTitle":223,"status":156,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},"NCT01388504","Nitrites in Acute Myocardial Infarction",[52,53],"2014-01","2011-07",200,[229],"Acute ST Elevation Myocardial Infarction",[211],{"trials":232,"activeCount":62},[],{"trials":234,"activeCount":62},[],{"intervention":236,"totalTrials":9,"cells":237},"Melatonin",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":252,"PHASE3":264,"PHASE4":266,"NA":268},{"trials":239,"activeCount":62},[],{"trials":241,"activeCount":62},[242],{"nctId":243,"briefTitle":244,"status":156,"phases":245,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":251},"NCT01724424","Melatonin in Healthy Volunteers",[51],"2013-05","2012-06",20,[250],"Sepsis",[236,236,236,236],{"trials":253,"activeCount":62},[254],{"nctId":255,"briefTitle":256,"status":257,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":62,"conditions":262,"interventions":263},"NCT02319265","Dose Assessment of Melatonin in Sepsis Trial","WITHDRAWN",[51,52],"2019-06","2019-12","2017-04",[250],[236],{"trials":265,"activeCount":62},[],{"trials":267,"activeCount":62},[],{"trials":269,"activeCount":62},[],{"intervention":271,"totalTrials":58,"cells":272},"Sodium Nitrate",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":288,"PHASE4":290,"NA":292},{"trials":274,"activeCount":62},[],{"trials":276,"activeCount":62},[],{"trials":278,"activeCount":62},[279],{"nctId":280,"briefTitle":281,"status":156,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":137,"conditions":285,"interventions":287},"NCT02078921","The Effects of Inorganic Nitrate on Cardiac Muscle in Angina",[52],"2014-12","2012-10",[286],"Chronic Stable Angina",[271],{"trials":289,"activeCount":62},[],{"trials":291,"activeCount":62},[],{"trials":293,"activeCount":62},[],{"intervention":295,"totalTrials":58,"cells":296},"AKL 1",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":311,"PHASE4":313,"NA":315},{"trials":298,"activeCount":62},[],{"trials":300,"activeCount":62},[],{"trials":302,"activeCount":62},[303],{"nctId":304,"briefTitle":305,"status":156,"phases":306,"completion":307,"start":308,"enrollment":185,"conditions":309,"interventions":310},"NCT00407524","AKL 1 Asthma Study",[52],"2005-03","2003-10",[18],[295],{"trials":312,"activeCount":62},[],{"trials":314,"activeCount":62},[],{"trials":316,"activeCount":62},[],{"intervention":318,"totalTrials":58,"cells":319},"Cysteamine",{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":321,"activeCount":62},[],{"trials":323,"activeCount":62},[],{"trials":325,"activeCount":62},[326],{"nctId":327,"briefTitle":328,"status":156,"phases":329,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":336},"NCT02212431","First Study of Oral Cysteamine in Cystic Fibrosis",[51,52],"2015-03","2015-04","2014-08",10,[335],"Cystic Fibrosis",[318],{"trials":338,"activeCount":62},[],{"trials":340,"activeCount":62},[],{"trials":342,"activeCount":62},[],{"intervention":344,"totalTrials":58,"cells":345},"Perhexiline",{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":347,"activeCount":62},[],{"trials":349,"activeCount":62},[],{"trials":351,"activeCount":62},[352],{"nctId":353,"briefTitle":354,"status":156,"phases":355,"primaryCompletion":183,"completion":183,"start":356,"enrollment":137,"conditions":357,"interventions":359},"NCT00839228","Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome",[52],"2009-03",[358],"Diastolic Heart Failure",[344],{"trials":361,"activeCount":62},[],{"trials":363,"activeCount":62},[],{"trials":365,"activeCount":62},[],{"intervention":367,"totalTrials":58,"cells":368},"Tacrolimus",{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":382,"PHASE4":384,"NA":386},{"trials":370,"activeCount":62},[],{"trials":372,"activeCount":62},[],{"trials":374,"activeCount":62},[375],{"nctId":376,"briefTitle":377,"status":156,"phases":378,"enrollment":248,"conditions":379,"interventions":381},"NCT01233570","Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease",[52],[380],"Crohn Disease",[367],{"trials":383,"activeCount":62},[],{"trials":385,"activeCount":62},[],{"trials":387,"activeCount":62},[],{"intervention":389,"totalTrials":58,"cells":390},"Topical NO",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":392,"activeCount":62},[],{"trials":394,"activeCount":62},[],{"trials":396,"activeCount":62},[397],{"nctId":398,"briefTitle":399,"status":156,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":407},"NCT02015260","A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts",[52],"2003-05","2001-09",299,[405,406],"Anogenital Warts","Condylomata Acuminata",[389],{"trials":409,"activeCount":62},[],{"trials":411,"activeCount":62},[],{"trials":413,"activeCount":62},[],{"intervention":415,"totalTrials":58,"cells":416},"Acute Inflammatory Activation study",{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":418,"activeCount":62},[],{"trials":420,"activeCount":62},[],{"trials":422,"activeCount":62},[],{"trials":424,"activeCount":62},[],{"trials":426,"activeCount":62},[],{"trials":428,"activeCount":62},[429],{"nctId":430,"briefTitle":431,"status":156,"phases":432,"primaryCompletion":433,"completion":433,"start":434,"enrollment":435,"conditions":436,"interventions":438},"NCT02897739","Pathogenesis of Acute Stress Induced (Tako-tsubo) Cardiomyopathy: Energy Shut-Down or Intense Inflammation?",[],"2019-03","2015-08",77,[437],"Tako-tsubo Cardiomyopathy",[415],{"intervention":440,"totalTrials":58,"cells":441},"Dovobet, neotigason, etanercept, adalimumab. infliximab",{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":452},{"trials":443,"activeCount":62},[],{"trials":445,"activeCount":62},[],{"trials":447,"activeCount":62},[],{"trials":449,"activeCount":62},[],{"trials":451,"activeCount":62},[],{"trials":453,"activeCount":62},[454],{"nctId":455,"briefTitle":456,"status":156,"phases":457,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":463},"NCT01233583","Regulatory T-cells in Psoriasis Patients as Targets for Therapy",[],"2013-09","2010-06",38,[462],"Psoriasis",[440],{"intervention":465,"totalTrials":58,"cells":466},"Blood test",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":468,"activeCount":62},[],{"trials":470,"activeCount":62},[],{"trials":472,"activeCount":62},[],{"trials":474,"activeCount":62},[],{"trials":476,"activeCount":62},[],{"trials":478,"activeCount":62},[479],{"nctId":480,"briefTitle":481,"status":482,"phases":483,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":488},"NCT05268913","Towards Early Detection of Breast Cancer in High Risk Population","UNKNOWN",[],"2024-05-01","2022-03-01",120,[23],[465]]